Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| ILT-M5252 | Mouse | Mouse gp130 / CD130 / IL-6 R beta Protein, Fc Tag |  |
|
|
| ILT-M52H1 | Mouse | Mouse gp130 / CD130 / IL-6 R beta Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tocilizumab | rhPM-1; RO-48775533; RG-1569; MRA; HPM-1; MRA-SC; R-1569 | Approved | Chugai Pharmaceutical Co Ltd | Actemra, RoActemra, 雅美罗, Actemra/RoActemra, Acterma | Japan | Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD); Arthritis, Juvenile | null | 2005-04-11 | Uveitis, Posterior; Polymyalgia Rheumatica; Takayasu Arteritis; Multicentric Castleman's Disease (MCD); systemic sclerosis-associated interstitial lung disease; Breast Neoplasms; Coronavirus Infections; Lupus Erythematosus, Systemic; Coronary Disease; Pulmonary Arterial Hypertension; Fever; Coronaviridae Infections; Lymphoma; Pleural Effusion, Malignant; Stroke; Inflammation; Rejection in heart transplantation; Pulmonary Disease, Chronic Obstructive; Uveitis; Osteoarthritis; Panuveitis; Non-ST Elevated Myocardial Infarction; Carcinoma, Hepatocellular; Anemia, Sickle Cell; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Kidney Failure, Chronic; Myocardial Infarction; Solid tumours; Non-radiographic axial spondyloarthritis; Cytokine Release Syndrome; HIV Infections; Acute Chest Syndrome; Diabetes Mellitus, Type 1; Craniopharyngioma; Motor Neuron Disease; Polymyositis; Schnitzler Syndrome; Giant Cell Arteritis; Uveitis, Intermediate; Pneumonia; Hematologic Neoplasms; Polyarticular Juvenile Idi | Details |
| Tocilizumab biosimilar (Bio-Thera Solutions) | BAT-1806; BIIB-800 | Approved | Bio-Thera Solutions Ltd | 施瑞立, TOFIDENCE | Mainland China | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome | Bio-Thera Solutions Ltd | 2023-01-16 | Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Arthritis, Juvenile | Details |
| Satralizumab | RG-6168; SA-237 | Approved | Chugai Pharmaceutical Co Ltd | Enspryng, エンスプリング | Japan | Neuromyelitis Optica | Chugai Pharmaceutical Co Ltd | 2020-06-29 | Myasthenia Gravis; Brain Ischemia; Graves Ophthalmopathy; Neuromyelitis Optica; Pulmonary Arterial Hypertension; Encephalitis; Subarachnoid Hemorrhage; Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Details |
| Sarilumab | SAR-153191; REGN-88 | Approved | Sanofi | Kevzara | United States | Arthritis, Rheumatoid | Sanofi-Synthelabo | 2017-05-22 | Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Sarcoidosis; Mastocytosis, Systemic; Arthritis, Juvenile; Polymyalgia Rheumatica; Severe Acute Respiratory Syndrome; Uveitis | Details |
| Tocilizumab biosimilar (Livzon Group) | LZM-008 | Approved | Livzon Pharmaceutical Group Inc | 安维泰 | Mainland China | Arthritis, Rheumatoid | Livzon Mabpharm Inc | 2023-01-18 | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (Fresenius kabi) | MSB-11456 | Approved | Merck Serono | Tyenne® | EU | Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis; Coronavirus Disease 2019 (COVID-19) | Fresenius Kabi Deutschland Gmbh | 2023-09-15 | Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| Tocilizumab | rhPM-1; RO-48775533; RG-1569; MRA; HPM-1; MRA-SC; R-1569 | Approved | Chugai Pharmaceutical Co Ltd | Actemra, RoActemra, 雅美罗, Actemra/RoActemra, Acterma | Japan | Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD); Arthritis, Juvenile | null | 2005-04-11 | Uveitis, Posterior; Polymyalgia Rheumatica; Takayasu Arteritis; Multicentric Castleman's Disease (MCD); systemic sclerosis-associated interstitial lung disease; Breast Neoplasms; Coronavirus Infections; Lupus Erythematosus, Systemic; Coronary Disease; Pulmonary Arterial Hypertension; Fever; Coronaviridae Infections; Lymphoma; Pleural Effusion, Malignant; Stroke; Inflammation; Rejection in heart transplantation; Pulmonary Disease, Chronic Obstructive; Uveitis; Osteoarthritis; Panuveitis; Non-ST Elevated Myocardial Infarction; Carcinoma, Hepatocellular; Anemia, Sickle Cell; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Kidney Failure, Chronic; Myocardial Infarction; Solid tumours; Non-radiographic axial spondyloarthritis; Cytokine Release Syndrome; HIV Infections; Acute Chest Syndrome; Diabetes Mellitus, Type 1; Craniopharyngioma; Motor Neuron Disease; Polymyositis; Schnitzler Syndrome; Giant Cell Arteritis; Uveitis, Intermediate; Pneumonia; Hematologic Neoplasms; Polyarticular Juvenile Idi | Details |
| Tocilizumab biosimilar (Bio-Thera Solutions) | BAT-1806; BIIB-800 | Approved | Bio-Thera Solutions Ltd | 施瑞立, TOFIDENCE | Mainland China | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome | Bio-Thera Solutions Ltd | 2023-01-16 | Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Arthritis, Juvenile | Details |
| Satralizumab | RG-6168; SA-237 | Approved | Chugai Pharmaceutical Co Ltd | Enspryng, エンスプリング | Japan | Neuromyelitis Optica | Chugai Pharmaceutical Co Ltd | 2020-06-29 | Myasthenia Gravis; Brain Ischemia; Graves Ophthalmopathy; Neuromyelitis Optica; Pulmonary Arterial Hypertension; Encephalitis; Subarachnoid Hemorrhage; Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Details |
| Sarilumab | SAR-153191; REGN-88 | Approved | Sanofi | Kevzara | United States | Arthritis, Rheumatoid | Sanofi-Synthelabo | 2017-05-22 | Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Sarcoidosis; Mastocytosis, Systemic; Arthritis, Juvenile; Polymyalgia Rheumatica; Severe Acute Respiratory Syndrome; Uveitis | Details |
| Tocilizumab biosimilar (Livzon Group) | LZM-008 | Approved | Livzon Pharmaceutical Group Inc | 安维泰 | Mainland China | Arthritis, Rheumatoid | Livzon Mabpharm Inc | 2023-01-18 | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (Fresenius kabi) | MSB-11456 | Approved | Merck Serono | Tyenne® | EU | Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis; Coronavirus Disease 2019 (COVID-19) | Fresenius Kabi Deutschland Gmbh | 2023-09-15 | Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
| Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | Details | |
| CMAB806 | CMAB-806 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
| Levilimab | BCD-089 | Phase 3 Clinical | Biocad | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| Olamkicept | FE-999301; CR-5/18; TJ-301; FE-301 | Phase 2 Clinical | Conaris Research Institute | Colitis, Ulcerative | Details |
| Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Weizmann Institute Of Science | Peripheral Nervous System Diseases; Diabetic Neuropathies | Details |
| VDJ-001 | Phase 2 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) | Details | |
| Tocilizumab Biosimilar (qyuns) | QX-003-S | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Arthritis, Rheumatoid | Details |
| Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
| Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | Details | |
| CMAB806 | CMAB-806 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
| Levilimab | BCD-089 | Phase 3 Clinical | Biocad | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| Olamkicept | FE-999301; CR-5/18; TJ-301; FE-301 | Phase 2 Clinical | Conaris Research Institute | Colitis, Ulcerative | Details |
| Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Weizmann Institute Of Science | Peripheral Nervous System Diseases; Diabetic Neuropathies | Details |
| VDJ-001 | Phase 2 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) | Details | |
| Tocilizumab Biosimilar (qyuns) | QX-003-S | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.
A-Z
